Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Supplementary Material 1 from First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies
  1. Home
  2. Publications
  3. Supplementary Material 1 from First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies

Supplementary Material 1 from First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies

Authors:
  • NLNehal J. Lakhani
    Nehal J. Lakhani
  • KPKyriakos P. Papadopoulos
    Kyriakos P. Papadopoulos
  • MJMelissa Lynne Johnson
    Melissa Lynne Johnson
  • HPHaeseong Park
    Haeseong Park
  • DWDing Wang
    Ding Wang
  • TYTimothy A. Yap
    Timothy A. Yap
  • ADAfshin Dowlati
    Afshin Dowlati
  • RMRobert G. Maki
    Robert G. Maki
  • SUSusanna Ulahannan
    Susanna Ulahannan
  • FLFilipa Lynce
    Filipa Lynce
  • KKKaren Kelly
    Karen Kelly
  • SWStephen Williamson
    Stephen Williamson

Open Access
Publisher website
Google Scholar
  • 16 December 2024
    • other
    • Published by American Association for Cancer Research (AACR)
    • DOI:10.1158/1078-0432.28032364
Abstract
No abstract available
Keywords
  • BIOLOGICAL AGENTS & THERAPIES
  • CLINICAL TRIAL RESULTS
  • DRUG TARGETS
  • IMMUNOTHERAPY
  • PROGRESSION, INVASION & METASTASIS
  • METASTASIS
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.